Literature DB >> 12559340

Coronary artery bypass grafting (CABG) after initially successful percutaneous transluminal coronary angioplasty (PTCA): a review of 17 years experience.

M S Barakate1, J M Hemli, C F Hughes, P G Bannon, M D Horton.   

Abstract

OBJECTIVE: Patients who undergo successful percutaneous transluminal coronary angioplasty (PTCA) may subsequently require operative myocardial revascularization. This review examines whether prior successful PTCA alters outcomes following subsequent coronary artery bypass grafting (CABG). The costs of interventional cardiology procedures and definitive surgery were also examined.
METHODS: From January 1981 through December 1997, 361 patients underwent CABG following initially successful PTCA (interval group). This group was compared with 11,909 patients who underwent CABG as the primary intervention for coronary artery disease (control group).
RESULTS: The average time interval to CABG following initial PTCA was 13.7 months. The post-CABG myocardial infarction rate was 4% for patients in the interval group and 3% for patients in the control group. The 30-day mortality was similar for both patient groups (2%). For the interval group, the average cost of total interventional management was 24,220 dollars per patient. This included average costs of 13,873 dollars for CABG and 10,347 dollars for all preoperative interventional cardiology procedures.
CONCLUSION: There is little doubt that PTCA procedures may provide successful myocardial revascularization. However, these procedures often need to be repeated over time and may serve only to delay coronary surgery, at substantial financial and personal cost. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Year:  2003        PMID: 12559340     DOI: 10.1016/s1010-7940(02)00764-9

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Previous percutaneous coronary intervention increases morbidity after coronary artery bypass grafting.

Authors:  Gaurav S Mehta; Damien J LaPar; Castigliano M Bhamidipati; John A Kern; Irving L Kron; Gilbert R Upchurch; Gorav Ailawadi
Journal:  Surgery       Date:  2012-04-11       Impact factor: 3.982

2.  Does really previous stenting affect graft patency following CABG? A 5-year follow-up: The effect of PCI on graft survival.

Authors:  Murat Çetin Songur; Sertan Özyalçin; Anıl Özen; Erdal Şimşek; Ümit Kervan; İrfan Taşoğlu; Sadi Kaplan; Kenan Köse; Ahmet Tulga Ulus
Journal:  Heart Vessels       Date:  2015-01-31       Impact factor: 2.037

3.  Prior percutaneous coronary intervention and outcomes in patients after coronary artery bypass grafting: a meta-analysis of 308,284 patients.

Authors:  Hongliang Zhang; Zhenyan Zhao; Jing Yao; Jie Zhao; Tao Hou; Moyang Wang; Yanlu Xu; Bincheng Wang; Guannan Niu; Yonggang Sui; Guangyuan Song; Yongjian Wu
Journal:  Ther Adv Chronic Dis       Date:  2022-05-13       Impact factor: 4.970

4.  Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG.

Authors:  Sandra Eifert; Helmut Mair; Anne-Laure Boulesteix; Eckehard Kilian; Martin Adamczak; Bruno Reichart; Peter Lamm
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

5.  Immediate Postoperative Complications in Patients Undergoing CABG; Investigating the Role of Prior Coronary Stenting.

Authors:  Sohrab Negargar; Shahriar Anvari; Kyomars Abbasi; Elgar Enamzadeh
Journal:  J Cardiovasc Thorac Res       Date:  2014-12-30

6.  Quality of Life in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA).

Authors:  Fatemeh Bahramnezhad; Mahboobeh Khajeh; Mahmoud Shiri; Parvaneh Asgari; Pouya Farokhnezhad Afshar
Journal:  Glob J Health Sci       Date:  2015-03-18

7.  Impact of prior coronary stenting on the outcome of subsequent coronary artery bypass grafting.

Authors:  Yu-Ting Cheng; Shao-Wei Chen; Chih-Hsiang Chang; Pao-Hsien Chu; Dong-Yi Chen; Victor Chien-Chia Wu; Kuo-Sheng Liu; Yu-Yun Nan; Feng-Chun Tsai; Pyng-Jing Lin
Journal:  Biomed J       Date:  2017-05-31       Impact factor: 4.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.